Key points are not available for this paper at this time.
Pyrotinib showed promising antitumor activity and an acceptable safety profile in chemotherapy-treated patients with HER2-mutant NSCLC.
Share your take
Add a clinician perspective alongside expert commentary.
Zhou et al. (2020) studied this question.